Beam Therapeutics

BEAM

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$288k

Combined value at quarter end

Last quarter

0 bought

1 sold or trimmed

Price at Q2 ’26 end

$34.32

+44.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+21.4%Q1 ’24

-29.1%Q2 ’24

+4.6%Q3 ’24

+1.2%Q4 ’24

+14.2%Q4 ’25

-14.0%Q1 ’26

+44.0%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23

1Q1 ’24

1Q2 ’24

1Q3 ’24

1Q4 ’24

0Q1 ’25

0Q2 ’25

2Q3 ’25

1Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Beam Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Beam Therapeutics

Horizon Kinetics	0.0%$288k	$288k	Trimmed -4.6%	4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Beam Therapeutics
		Bought or sold				Filing
16 Oct 2026	Evans John M.CEO	▼ Sold	25,000	$23.98	$600k	Form 4
15 Oct 2026	Evans John M.CEO	▼ Sold	25,000	$23.57	$589k	Form 4
1 Oct 2026	Cavanagh Bethany JSVP, Finance and Treasurer	▼ Sold	187	$24.41	$5k	Form 4
27 Jul 2026	Simon AmyChief Medical Officer	▼ Sold	16,667	$25.74	$429k	Form 4

About the company

Sector: Health care · Biological Products, (No Diagnostic Substances)
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 103m at 28 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$18k2019

$24k2020

$51.8m2021

$60.9m2022

$378m2023

$63.5m2024

$140m2025

Beam Therapeutics revenue and net income by year
Year	Revenue	Net income
2025	$140m	−$80.0m
2024	$63.5m	−$377m
2023	$378m	−$133m
2022	$60.9m	−$289m
2021	$51.8m	−$371m
2020	$24k	−$195m
2019	$18k	−$78.3m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.